Synthesis of fluorinated acyclic nucleoside phosphonates with 5-azacytosine base moiety

被引:5
作者
Pomeisl, Karel [1 ,2 ]
Krecmerova, Marcela [1 ]
Pohl, Radek [1 ]
Snoeck, Robert [3 ]
Andrei, Graciela [3 ]
机构
[1] Czech Acad Sci, Inst Organ Chem & Biochem, Flemingovo Nam 2, CZ-16610 Prague 6, Czech Republic
[2] Czech Acad Sci, Inst Phys, Slovance 1999-2, Prague 18221 8, Czech Republic
[3] Katholieke Univ Leuven, Rega Inst Med Res, Herestr 49,Box 1043, B-3000 Leuven, Belgium
关键词
Acyclic nucleoside phosphonates; 5-Azacytosine; Fluorinated nucleotides; Prodrugs; Phosphonates; PHOSPHORYLASE PD-ECGF; ANTIVIRAL ACTIVITY; MEDICINAL CHEMISTRY; DERIVATIVES; PRODRUGS; ANALOGS; PYRIMIDINE; CIDOFOVIR;
D O I
10.1016/j.tet.2019.130529
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
With respect to the strong antiviral activity of (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine various types of its side chain fluorinated analogues were prepared. The title compound, (S)-1-[3-fluoro-2-(phosphonomethoxy)propyl]-5-azacytosine (FPMP-5-azaC) was synthesised by the condensation reaction of (S)-2-[(diisopropoxyphosphoryl)methoxy)-3-fluoropropyl p-toluenesulfonate with a sodium salt of 5-azacytosine followed by separation of appropriate N-1 and O-2 regioisomers and ester hydrolysis. Transformations of FPMP-5-azaC to its 5,6-dihydro-5-azacytosine counterpart, amino acid phosphoramidate prodrugs and systems with an annelated five-membered imidazole ring, i.e. imidazo [1,2-a][1,3,5]triazine derivatives were also carried out. 1-(2-Phosphonomethoxy-3,3,3-trifluoropropyl)-5-azacytosine was prepared from 5-azacytosine and trifluoromethyloxirane to form 1-(3,3,3-trifluoro-2-hydroxypropyl)-5-azacytosine which was treated with diisopropyl bromomethane-phosphonate followed by deprotection of esters. Antiviral activity of all newly prepared compounds was studied. FPMP-5-azaC diisopropyl ester inhibited the replication of herpes viruses with EC50 values that were about three times higher than that of the reference anti-HCMV drug ganciclovir without displaying cytotoxicity. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页数:13
相关论文
共 41 条
[1]  
BAASNER B, 1999, METHODS ORGANIC CHEM
[2]   9-[(2RS)-3-FLUORO-2-PHOSPHONYLMETHOXYPROPYL] DERIVATIVES OF PURINES - A CLASS OF HIGHLY SELECTIVE ANTIRETROVIRAL AGENTS INVITRO AND INVIVO [J].
BALZARINI, J ;
HOLY, A ;
JINDRICH, J ;
DVORAKOVA, H ;
HAO, Z ;
SNOECK, R ;
HERDEWIJN, P ;
JOHNS, DG ;
DECLERCQ, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (11) :4961-4965
[3]   Medicinal Chemistry of Fluorinated Cyclic and Acyclic Nucleoside Phosphonates [J].
Baszczynski, Ondrej ;
Janeba, Zlatko .
MEDICINAL RESEARCH REVIEWS, 2013, 33 (06) :1304-1344
[4]   Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines [J].
Baszczynski, Ondrej ;
Jansa, Petr ;
Dracinsky, Martin ;
Klepetarova, Blanka ;
Holy, Antonin ;
Votruba, Ivan ;
de Clercq, Erik ;
Balzarini, Jan ;
Janeba, Zlatko .
BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (07) :2114-2124
[5]   Fluorinated nucleosides as an important class of anticancer and antiviral agents [J].
Cavaliere, Alessandra ;
Probst, Katrin C. ;
Westwell, Andrew D. ;
Slusarczyk, Magdalena .
FUTURE MEDICINAL CHEMISTRY, 2017, 9 (15) :1809-1833
[6]   Acyclic nucleoside phosphonates: A key class of antiviral drugs [J].
De Clercq, E ;
Holy, A .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (11) :928-940
[7]   The Acyclic Nucleoside Phosphonates (ANPs): Antonin Holy's Legacy [J].
De Clercq, Erik .
MEDICINAL RESEARCH REVIEWS, 2013, 33 (06) :1278-1303
[8]   The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond [J].
De Clercq, Erik .
BIOCHEMICAL PHARMACOLOGY, 2011, 82 (02) :99-109
[9]   Study of chemical stability of antivirally active 5-azacytosine acyclic nucleoside phosphonates using NMR spectroscopy [J].
Dracinsky, Martin ;
Krecmerova, Marcela ;
Holy, Antonin .
BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (14) :6778-6782
[10]   Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide [J].
Gotham, Dzintars ;
Hill, Andrew ;
Pozniak, Anton L. .
CURRENT OPINION IN HIV AND AIDS, 2017, 12 (04) :324-333